Clinical Trials
48 trialsMOMENTUM-1
RTOG Foundation, Inc.
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
St. Joseph's Hospital and Medical Center, Phoenix
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
ELUMEN
Central Hospital, Nancy, France
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Jonsson Comprehensive Cancer Center
DCLNF1
The University of Texas Health Science Center, Houston
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
CEVOREM
Assistance Publique Hopitaux De Marseille
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
University of Michigan Rogel Cancer Center
RTOG 0913
Radiation Therapy Oncology Group
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
NYU Langone Health
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Alliance for Clinical Trials in Oncology
NFC-RAD001
University of Alabama at Birmingham
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
University of Michigan Rogel Cancer Center
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
UNC Lineberger Comprehensive Cancer Center
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Dana-Farber Cancer Institute
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
AFINF2
Assistance Publique - Hôpitaux de Paris
EXIST-2
Novartis
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Novartis
EXIST-1
Novartis
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
St. Jude Children's Research Hospital
PheoCarcRAD001
Seoul National University Hospital
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
St. Jude Children's Research Hospital
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Novartis
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Fox Chase Cancer Center
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis